ADVAIR 250 DISKUS POWDER

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

SALMETEROL (SALMETEROL XINAFOATE); FLUTICASONE PROPIONATE

Beschikbaar vanaf:

GLAXOSMITHKLINE INC

ATC-code:

R03AK06

INN (Algemene Internationale Benaming):

SALMETEROL AND FLUTICASONE

Dosering:

50MCG; 250MCG

farmaceutische vorm:

POWDER

Samenstelling:

SALMETEROL (SALMETEROL XINAFOATE) 50MCG; FLUTICASONE PROPIONATE 250MCG

Toedieningsweg:

INHALATION

Eenheden in pakket:

28,60 DOSES

Prescription-type:

Prescription

Therapeutisch gebied:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

Product samenvatting:

Active ingredient group (AIG) number: 0238341002; AHFS:

Autorisatie-status:

APPROVED

Autorisatie datum:

1999-09-03

Productkenmerken

_ _
_ _
_Page 1 of 70_
PR
ADVAIR DISKUS
fluticasone propionate and salmeterol inhalation powder USP
Pr
ADVAIR DISKUS _100_
100 mcg fluticasone propionate and 50 mcg salmeterol (as the xinafoate
salt)
Pr
ADVAIR DISKUS _250_
250 mcg fluticasone propionate and 50 mcg salmeterol (as the xinafoate
salt)
Pr
ADVAIR DISKUS _500_
500 mcg fluticasone propionate and 50 mcg salmeterol (as the xinafoate
salt)
PR
ADVAIR
fluticasone propionate and salmeterol pressurised inhalation,
suspension BP
Pr
ADVAIR _125_
125 mcg fluticasone propionate and 25 mcg salmeterol (as the xinafoate
salt)
Pr
ADVAIR _250_
250 mcg fluticasone propionate and 25 mcg salmeterol (as the xinafoate
salt)
Corticosteroid and Bronchodilator for Oral Inhalation
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Date of Revision:
June 17, 2020
Submission Control No: 237271
_© 2020 GSK group of companies or its licensor_
Trademarks are owned by or licensed to the GSK group of companies.
_ _
_ _
_Page 2 of 70_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................................
3
SUMMARY
PRODUCT
INFORMATION
...............................................................................................
3
INDICATIONS
AND
CLINICAL
USE
.....................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................
4
WARNINGS
AND
PRECAUTIONS
........................................................................................................
4
ADVERSE
REACTIONS
........................................................................................................................
15
DRUG
INTERACTIONS
........................................................................................................................
24
DOSAGE
AND
ADMINISTRATION..........................................................................